|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AGREE II items | AAOS[26] | ACR[27] | Eular[28-30] | Eular[31] | Kjenken[32] | NICE[33] | OARSI[34] | Ottawa Panel[35-39] | Peter et al. [42] | PhiladelphiaPanel[40-41] | RACGP[44] | Roddy et al. [43] |
|  | Domain 1. Scope and Purpose |
| 1 | 7 | 7 | 6 | 7 | 5 | 4 | 6 | 6 | 7 | 7 | 5 | 5 | 5 | 7 | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 7 |
| 2 | 4 | 6 | 6 | 6 | 2 | 2 | 4 | 6 | 4 | 5 | 6 | 4 | 3 | 5 | 7 | 7 | 4 | 6 | 7 | 7 | 3 | 6 | 4 | 6 |
| 3 | 4 | 6 | 6 | 7 | 2 | 2 | 2 | 2 | 2 | 1 | 6 | 4 | 2 | 4 | 6 | 7 | 2 | 2 | 6 | 7 | 5 | 7 | 5 | 5 |
|  | Domain 2. Stakeholder Involvement |
| 4 | 4 | 7 | 7 | 7 | 4 | 7 | 6 | 7 | 3 | 1 | 6 | 7 | 5 | 7 | 6 | 7 | 5 | 7 | 6 | 7 | 5 | 7 | 5 | 7 |
| 5 | 1 | 3 | 4 | 2 | 1 | 1 | 5 | 5 | 1 | 1 | 7 | 5 | 3 | 1 | 4 | 2 | 3 | 3 | 1 | 2 | 2 | 5 | 1 | 1 |
| 6 | 7 | 6 | 6 | 6 | 1 | 2 | 6 | 5 | 5 | 2 | 7 | 6 | 7 | 7 | 6 | 7 | 5 | 7 | 7 | 7 | 7 | 7 | 4 | 2 |
|  | Domain 3. Rigour of Development |
| 7 | 4 | 7 | 5 | 6 | 7 | 7 | 7 | 7 | 4 | 5 | 3 | 1 | 6 | 7 | 6 | 6 | 5 | 5 | 5 | 6 | 7 | 7 | 5 | 5 |
| 8 | 6 | 6 | 5 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 7 | 5 | 7 | 7 | 7 | 7 | 3 | 2 | 7 | 7 | 6 | 6 | 5 | 4 |
| 9 | 4 | 6 | 5 | 6 | 2 | 4 | 4 | 5 | 3 | 2 | 2 | 7 | 2 | 4 | 7 | 5 | 3 | 2 | 5 | 5 | 5 | 3 | 4 | 5 |
| 10 | 6 | 7 | 7 | 7 | 4 | 7 | 5 | 2 | 6 | 7 | 2 | 7 | 6 | 6 | 4 | 7 | 4 | 4 | 7 | 7 | 3 | 7 | 6 | 7 |
| 11 | 4 | 7 | 5 | 7 | 7 | 5 | 6 | 6 | 4 | 1 | 7 | 7 | 7 | 7 | 5 | 5 | 5 | 5 | 2 | 2 | 6 | 7 | 4 | 7 |
| 12 | 6 | 7 | 5 | 7 | 5 | 3 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 6 | 7 | 7 | 7 | 6 | 7 | 6 | 7 |
| 13 | 6 | 7 | 2 | 3 | 1 | 2 | 2 | 1 | 4 | 5 | 5 | 3 | 4 | 5 | 3 | 5 | 3 | 3 | 7 | 7 | 6 | 7 | 1 | 1 |
| 14 | 4 | 6 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 7 | 6 | 4 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 | 1 | 1 |
|  | Domain 4. Clarity of Presentation |
| 15 | 5 | 7 | 5 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 7 | 5 | 7 | 6 | 7 | 5 | 5 | 5 | 7 | 6 | 6 |
| 16 | 7 | 5 | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 7 | 5 | 6 | 7 | 7 | 5 | 5 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 |
| 17 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 4 | 4 | 7 | 7 | 5 | 5 | 7 | 7 | 7 | 7 |
|  | Domain 5. Applicability |
| 18 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 3 | 2 | 4 | 2 | 1 | 1 | 6 | 6 | 4 | 1 | 1 | 1 |
| 19 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 4 | 1 | 1 |
| 20 | 1 | 1 | 1 | 2 | 5 | 5 | 1 | 1 | 1 | 1 | 7 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 21 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|  | Domain 6. Editorial Independence |
| 22 | 3 | 6 | 4 | 3 | 3 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 3 | 4 | 3 | 3 | 3 | 6 | 3 | 3 |
| 23 | 6 | 6 | 2 | 2 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 7 | 7 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 3 | 3 |
|  | Overall Assessment |
| A1 | 5 | 6 | 5 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 6 | 4 | 5 | 5 | 6 | 4 | 4 | 5 | 5 | 5 | 7 | 6 | 6 |
| B2 | Y | Y | Y | Y | M | M | Y | Y | M | M | Y | Y | M | Y | Y | Y | M | M | Y | Y | Y | Y | Y | Y |

ACR: American College of Rheumatology; EULAR: The European League against rheumatism; NICE: National Institute for health and Clinical Excellence; OARSI: Osteoarthritis Research Society International; RACGP: Royal Australian College of General Practitioners

 **LEGEND**

  Evaluator 1 (KTA & LB)

 Evaluator 2 (PR)

1A: Rate the overall quality of this guideline.

2B: I would recommend this guideline for use.

Y: Yes

M: Yes, with modification

N: No